Due to the co-existing prostate-specific antigen (PSA) raising and lowering factors, the commonly used PSA screening test often lacks sufficient sensitivity or specificity to accurately predict prostate cancer (PCa).¹ Spermine, a novel non-prostate massage urine biomarker, was recently shown to be

Bladder cancer is the 9^th most common malignancy world-wide.¹ On April 12, 2019, the U.S. Food and Drug Administration (FDA) approved erdafitinib, a novel personalized treatment targeting genetic alterations of